Intervention not reported
Lung function Mean percentage change in FVC (% predicted) · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Nutritional status BMI · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Time to first exacerbation requiring intravenous antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Antibiotic resistance patterns following treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Ototoxicity An increase in auditory threshold of 20 dB or more over any frequency range · adults and children with cystic fibrosis
The intervention showed no clear difference in ototoxicity An increase in auditory threshold of 20 dB or more over… (low certainty).
1 finding from 1 review
Intervention not reported
Nephrotoxicity The percentage change in creatinine over baseline · adults and children with cystic fibrosis
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Alteplase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Alteplase may leads to higher serious adverse events compared with urokinase (low certainty).
1 finding from 1 review
All‐cause mortality · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in mortality compared with urokinase (low certainty).
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in serious adverse events compared with urokinase (low certainty).
1 finding from 1 review
All‐cause mortality · adult parapneumonic effusions and empyema
Alteplase showed no clear difference in mortality compared with urokinase (low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).
1 finding from 1 review
RR 0.71 [0.46, 1.1]
110 participants
Low
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review